Redeye is encouraged by the continuing geographical expansion, and that first sales have come from the Thermo Fischer deal (in Q3), but we make some downward adjustments to our financial forecasts. We reiterate our take on Devyser’s share offering attractive entry points for a relatively de-risked growth case, though somewhat lowering our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Devyser Diagnostics Q2 - An unnoticed high-quality growth case

© Modular Finance, source Nordic Press Releases